Agilent Technologies, Inc.

New York Stock Exchange
Back to all articles
Somewhat Bearish -25

Agilent Technologies Inc. stock (US00846U1016): Q1 2026 earnings miss by a cent as guidance points t - AD HOC NEWS

📉 Agilent Technologies reported Q1 2026 adjusted earnings per share of $1.36, missing analyst consensus estimates by $0.01.

💰 Revenue for the first quarter was approximately $1.80 billion, slightly below the projected $1.81 billion but showing a 7% year-over-year increase.

📅 The results were released on February 25, 2026, marking the company's start to its fiscal 2026 with modest growth amidst macroeconomic uncertainties.

🔮 Management issued Q2 2026 guidance projecting EPS between $1.39 and $1.42 with revenue near $1.8 billion, aligning closely with analyst forecasts.

📈 Long-term consensus estimates suggest earnings could rise from roughly $5.95 to $6.55 per share over the next year, indicating growth of just over 10%.

💵 The stock traded around $112.80 on May 13, 2026, and recently paid a quarterly dividend of $0.25 per share with an ex-dividend date of March 31, 2026.

🧬 Agilent's portfolio focuses on analytical instruments like chromatography and mass spectrometry used in pharmaceutical, biotechnology, and chemical markets.

⚙️ The business model combines upfront hardware sales with recurring revenue from consumables such as columns and reagents needed for installed base maintenance.

🔬 Diagnostic and genomics segments supply assays and instruments for clinical testing in areas like oncology and genetic analysis, tapping into precision medicine trends.

🛠 Service offerings including maintenance contracts, qualification support, and training help capture higher-margin revenue while deepening customer relationships.

⚖️ The narrow earnings miss is attributed to margin pressures or product mix effects rather than a loss of underlying growth drivers in core end markets.

🧪 Laboratory equipment faces recurring demand as customers run tests and maintain instruments, supporting stable cash flows despite budget constraints for some academic clients.

🏥 Solutions used in quality-control and clinical workflows are integral to research processes across various industries including environmental and chemical sectors.

Bullish Signals
  • Agilent Technologies reported a 7.0% year-over-year revenue growth in the first quarter of fiscal 2026, demonstrating solid demand across core end markets despite macroeconomic uncertainty.
  • The company raised its second-quarter 2026 guidance, projecting EPS between $1.39 and $1.42, with projections broadly aligned to analyst consensus for continued expansion.
  • Long-term consensus expectations indicate that earnings could rise from about $5.95 per share to $6.55 per share over the next year, representing growth of just over 10%.
  • Agilent maintains a recurring revenue model through consumables like columns and reagents sold alongside hardware, ensuring ongoing demand once instruments are installed in laboratories.
  • The company returns cash to shareholders via a regular quarterly dividend of $0.25 per share with an attractive dividend yield of about 0.90% at recent prices.
  • Service offerings in maintenance contracts and compliance support provide the opportunity to capture higher-margin service revenue and deepen customer relationships over time.
Risk Factors
  • Agilent Technologies missed Q1 2026 earnings-per-share expectations by $0.01, reporting $1.36 versus the consensus estimate of $1.37.
  • Revenue for the first quarter came in slightly below Wall Street projections at approximately $1.80 billion compared to the expected $1.81 billion.
  • The earnings miss suggests that margin pressures or unfavorable mix effects limited upside despite positive top-line growth.
  • Dividend yield is relatively low at 0.90% for a stock trading around $112.80, which may limit total return potential for income-focused investors.
Full Analysis
Agilent Technologies Inc. reported its fiscal 2026 first-quarter results on February 25, 2026, missing Wall Street expectations by one cent with adjusted earnings per share of $1.37 versus consensus estimates of $1.36, while revenue came in slightly below forecasts at approximately $1.80 billion compared to the expected $1.81 billion. Despite this narrow earnings miss, management indicated that the top-line trajectory remains positive with 7.0% year-over-year revenue growth, signaling continued demand for the company's analytical instruments and consumables in life science, pharmaceutical, and biotechnology sectors. The company’s performance reflects a mix of upfront hardware sales and recurring revenue streams from consumables such as columns and reagents, which provide stability once laboratory installations are established. Looking ahead, Agilent Technologies issued second-quarter 2026 guidance projecting adjusted EPS between $1.39 and $1.42 with revenue near $1.8 billion, figures that align closely with prevailing analyst forecasts. Consensus expectations for the coming year suggest earnings could grow from approximately $5.95 per share to $6.55 per share, representing over 10% growth driven by resilient demand in drug discovery, diagnostics, and genomics markets. The company also maintains a commitment to shareholder returns through a regular dividend program, with a recent quarterly payment of $0.25 per share yielding around 0.90% at recent price levels. Business-wise, Agilent focuses on chromatography, mass spectrometry, spectroscopy, and diagnostics platforms that serve critical roles in research, quality control, and clinical workflows across healthcare systems. The firm also leverages service offerings including maintenance contracts and compliance support to capture higher-margin revenue while addressing customer needs regarding cost pressures and staffing challenges. While regulatory dynamics in the diagnostics arena present certain sensitivities, the broader trend toward precision medicine and increased testing volumes supports long-term structural growth for Agilent’s portfolio of laboratory equipment and solutions.